Measles Clinical Trial
Official title:
Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.
Verified date | October 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal vaccine.
Status | Completed |
Enrollment | 1851 |
Est. completion date | March 17, 2009 |
Est. primary completion date | February 24, 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 14 Months |
Eligibility |
Inclusion Criteria: - Subjects for whom the investigator believes their parents/guardians can and will comply with the requirements of the protocol. - Male or female between 12 and 14 months of age at the time of first vaccination. - Written informed consent obtained from the parent/guardian of the subject. - Healthy subjects as established by medical history and clinical examination before entering into the study. - Have previously received 3 doses of 7-valent pneumococcal conjugate vaccine within the first year of life. Exclusion Criteria: - Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. - Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. - Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. - Planned administration/ administration of a vaccine not foreseen by the study protocol from 30 days prior to vaccination until 42 days after vaccination, except for influenza vaccine. - Previous vaccination against measles, mumps, rubella and/or varicella. - Previous vaccination against hepatitis A or receipt of a fourth dose of pneumococcal conjugate vaccine. - History of measles, mumps, rubella and/or varicella/zoster diseases. - Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the study. - Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination, including human immunodeficiency virus infection. - A family history of congenital or hereditary immunodeficiency. - History of allergic disease or reactions likely to be exacerbated by any component of the vaccines. - Major congenital defects or serious chronic illness. - History of any neurologic disorders or seizures. Uncomplicated febrile convulsions are not an exclusion criterion. - Residence in the same household as the following persons: - New-born infants (0-4 weeks of age). - Pregnant mother/women with a negative history of chickenpox disease and without recorded vaccination against chickenpox. - Pregnant women at or beyond 28 weeks gestation regardless of varicella vaccination status or varicella disease history. - Persons with known immunodeficiency. - Acute disease at the time of enrolment. All vaccines can be administered to persons with a minor illness. - Administration of polyclonal immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period. - Contra-indications to commercially available vaccines used in this study (Havrix®, Prevnar®, ProQuad®). |
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | Altoona | Pennsylvania |
United States | GSK Investigational Site | Amarillo | Texas |
United States | GSK Investigational Site | Anaheim | California |
United States | GSK Investigational Site | Anaheim | California |
United States | GSK Investigational Site | Arkansas City | Kansas |
United States | GSK Investigational Site | Baltimore | Maryland |
United States | GSK Investigational Site | Bardstown | Kentucky |
United States | GSK Investigational Site | Bellevue | Nebraska |
United States | GSK Investigational Site | Benton | Arkansas |
United States | GSK Investigational Site | Birmingham | Alabama |
United States | GSK Investigational Site | Birmingham | Alabama |
United States | GSK Investigational Site | Boone | North Carolina |
United States | GSK Investigational Site | Boynton Beach | Florida |
United States | GSK Investigational Site | Brainerd | Minnesota |
United States | GSK Investigational Site | Brentwood | Tennessee |
United States | GSK Investigational Site | Bridgeton | Missouri |
United States | GSK Investigational Site | Bristol | Tennessee |
United States | GSK Investigational Site | Bryan | Texas |
United States | GSK Investigational Site | Buena Park | California |
United States | GSK Investigational Site | Carrollton | Georgia |
United States | GSK Investigational Site | Cary | North Carolina |
United States | GSK Investigational Site | Centennial | Colorado |
United States | GSK Investigational Site | Charleston | South Carolina |
United States | GSK Investigational Site | Charlottesville | Virginia |
United States | GSK Investigational Site | Charlottesville | Virginia |
United States | GSK Investigational Site | Chesapeake | Virginia |
United States | GSK Investigational Site | Cincinnati | Ohio |
United States | GSK Investigational Site | Columbia | Missouri |
United States | GSK Investigational Site | Corpus Christi | Texas |
United States | GSK Investigational Site | Dalton | Georgia |
United States | GSK Investigational Site | Dayton | Ohio |
United States | GSK Investigational Site | DeKalb | Illinois |
United States | GSK Investigational Site | Downey | California |
United States | GSK Investigational Site | Dubuque | Iowa |
United States | GSK Investigational Site | Dubuque | Iowa |
United States | GSK Investigational Site | East Norriton | Pennsylvania |
United States | GSK Investigational Site | Eugene | Oregon |
United States | GSK Investigational Site | Fairfield | Ohio |
United States | GSK Investigational Site | Fall River | Massachusetts |
United States | GSK Investigational Site | Fargo | North Dakota |
United States | GSK Investigational Site | Fishers | Indiana |
United States | GSK Investigational Site | Fountain Valley | California |
United States | GSK Investigational Site | Frederick | Maryland |
United States | GSK Investigational Site | Fremont | California |
United States | GSK Investigational Site | Fresno | California |
United States | GSK Investigational Site | Gresham | Oregon |
United States | GSK Investigational Site | Hayward | California |
United States | GSK Investigational Site | Henderson | Nevada |
United States | GSK Investigational Site | Honolulu | Hawaii |
United States | GSK Investigational Site | Honolulu | Hawaii |
United States | GSK Investigational Site | Huber Heights | Ohio |
United States | GSK Investigational Site | Huntington | West Virginia |
United States | GSK Investigational Site | Huntington Beach | California |
United States | GSK Investigational Site | Indianapolis | Indiana |
United States | GSK Investigational Site | Johnson City | New York |
United States | GSK Investigational Site | Jonesboro | Arkansas |
United States | GSK Investigational Site | Kalamazoo | Michigan |
United States | GSK Investigational Site | Kansas City | Missouri |
United States | GSK Investigational Site | Kingsport | Tennessee |
United States | GSK Investigational Site | Kittanning | Pennsylvania |
United States | GSK Investigational Site | La Crosse | Wisconsin |
United States | GSK Investigational Site | Lafayette | Indiana |
United States | GSK Investigational Site | Lake Success | New York |
United States | GSK Investigational Site | Lakewood | California |
United States | GSK Investigational Site | Las Vegas | Nevada |
United States | GSK Investigational Site | Latrobe | Pennsylvania |
United States | GSK Investigational Site | Layton | Utah |
United States | GSK Investigational Site | Lexington | Kentucky |
United States | GSK Investigational Site | Little Rock | Arkansas |
United States | GSK Investigational Site | Louisville | Kentucky |
United States | GSK Investigational Site | Louisville | Kentucky |
United States | GSK Investigational Site | Louisville | Kentucky |
United States | GSK Investigational Site | Lubbock | Texas |
United States | GSK Investigational Site | Madison | Wisconsin |
United States | GSK Investigational Site | Marietta | Georgia |
United States | GSK Investigational Site | Marshfield | Wisconsin |
United States | GSK Investigational Site | Midlothian | Virginia |
United States | GSK Investigational Site | Mineola | New York |
United States | GSK Investigational Site | Minot | North Dakota |
United States | GSK Investigational Site | Nampa | Idaho |
United States | GSK Investigational Site | Nashville | Tennessee |
United States | GSK Investigational Site | New Albany | Indiana |
United States | GSK Investigational Site | Niles | Michigan |
United States | GSK Investigational Site | Oakland | California |
United States | GSK Investigational Site | Ogden | Utah |
United States | GSK Investigational Site | Omaha | Nebraska |
United States | GSK Investigational Site | Omaha | Nebraska |
United States | GSK Investigational Site | Opa-locka | Florida |
United States | GSK Investigational Site | Overland Park | Kansas |
United States | GSK Investigational Site | Owensboro | Kentucky |
United States | GSK Investigational Site | Paramount | California |
United States | GSK Investigational Site | Phoenix | Arizona |
United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
United States | GSK Investigational Site | Plantation | Florida |
United States | GSK Investigational Site | Pleasanton | California |
United States | GSK Investigational Site | Portage | Michigan |
United States | GSK Investigational Site | Provo | Utah |
United States | GSK Investigational Site | Raleigh | North Carolina |
United States | GSK Investigational Site | Richland | Michigan |
United States | GSK Investigational Site | Rochester | New York |
United States | GSK Investigational Site | Saint George | Utah |
United States | GSK Investigational Site | Saint Paul | Minnesota |
United States | GSK Investigational Site | San Antonio | Texas |
United States | GSK Investigational Site | San Antonio | Texas |
United States | GSK Investigational Site | San Antonio | Texas |
United States | GSK Investigational Site | San Antonio | Texas |
United States | GSK Investigational Site | San Francisco | California |
United States | GSK Investigational Site | San Jose | California |
United States | GSK Investigational Site | Sellersville | Pennsylvania |
United States | GSK Investigational Site | South Jordan | Utah |
United States | GSK Investigational Site | Springfield | Kentucky |
United States | GSK Investigational Site | Stevensville | Michigan |
United States | GSK Investigational Site | Stony Brook | New York |
United States | GSK Investigational Site | Sugar Land | Texas |
United States | GSK Investigational Site | Sylva | North Carolina |
United States | GSK Investigational Site | Syracuse | New York |
United States | GSK Investigational Site | Thornton | Colorado |
United States | GSK Investigational Site | Tifton | Georgia |
United States | GSK Investigational Site | Topeka | Kansas |
United States | GSK Investigational Site | Torrance | California |
United States | GSK Investigational Site | Tucker | Georgia |
United States | GSK Investigational Site | Tulsa | Oklahoma |
United States | GSK Investigational Site | Tuscaloosa | Alabama |
United States | GSK Investigational Site | Uniontown | Pennsylvania |
United States | GSK Investigational Site | Utica | New York |
United States | GSK Investigational Site | Vacaville | California |
United States | GSK Investigational Site | Vienna | Virginia |
United States | GSK Investigational Site | Virginia Beach | Virginia |
United States | GSK Investigational Site | Waukee | Iowa |
United States | GSK Investigational Site | West Covina | California |
United States | GSK Investigational Site | West Des Moines | Iowa |
United States | GSK Investigational Site | West Jordan | Utah |
United States | GSK Investigational Site | West Palm Beach | Florida |
United States | GSK Investigational Site | Westminster | Colorado |
United States | GSK Investigational Site | Wexford | Pennsylvania |
United States | GSK Investigational Site | White House Station | New Jersey |
United States | GSK Investigational Site | Wichita | Kansas |
United States | GSK Investigational Site | Woburn | Massachusetts |
United States | GSK Investigational Site | Woodstock | Georgia |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States,
Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, Mufson MA, Martin JM, Varman M, Grogg S, London A, Cambron P, Douha M, Nicholson O, da Costa C, Innis BL. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012 Aug;31(8):e133-40. doi: 10.1097/INF.0b013e318259fc8a. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV) | Seroresponse for antibodies to VZV is defined as the appearance post-vaccination of anti-VZV antibodies [concentration greater than or equal to the threshold of 75 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 25 mIU/mL before vaccination. | At Day 42 after vaccination | |
Primary | Concentration of Antibodies to Varicella Virus (VZV) | Concentrations are given as Geometric Mean Concentrations (GMCs). | At Day 42 after vaccination | |
Primary | Number of Subjects With Seroresponse for Antibodies to Mumps Virus | Seroresponse for antibodies to mumps virus is defined as the appearance post-vaccination of anti-mumps virus antibodies [titer greater than or equal to the threshold of 51 Effective Doses (ED50)] in the serum of subjects below the assay cut-off value of 24 ED50 before vaccination. | At Day 42 after vaccination | |
Primary | Number of Subjects With Seroresponse for Antibodies to Measles Virus | Seroresponse for antibodies to measles virus is defined as the appearance post-vaccination of anti-measles virus antibodies [concentration greater than or equal to the threshold of 200 milli-international units per milliliter (mIU/mL)] in the serum of subjects below the assay cut-off value of 150 mIU/mL before vaccination. | At Day 42 after vaccination | |
Primary | Number of Subjects With Seroresponse for Antibodies to Rubella Virus | Seroresponse for antibodies to rubella virus is defined as the appearance post-vaccination of anti-rubella virus antibodies [concentration greater than or equal to the threshold of 10 international units per milliliter (IU/mL)] in the serum of subjects below the assay cut-off value of 4 IU/mL before vaccination. | At Day 42 after vaccination | |
Primary | Concentration of Antibodies to Hepatitis A Virus (HAV) | Concentrations are given as Geometric Mean Concentrations (GMCs). | At Day 42 after vaccination | |
Primary | Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F | Concentrations are given as Geometric Mean Concentrations (GMCs). | At Day 42 after vaccination | |
Secondary | Antibody Titers to Mumps Virus | Data are expressed as Geometric Mean Titers (GMTs). The titer is the serum dilution giving a 50 percent reduction of the signal compared to a control without serum. | At Day 42 after vaccination | |
Secondary | Concentration of Antibodies to Measles Virus | Concentrations are given as Geometric Mean Concentrations (GMCs). | At Day 42 after vaccination | |
Secondary | Concentration of Antibodies to Rubella Virus | Concentrations are given as Geometric Mean Concentrations (GMCs). | At Day 42 after vaccination | |
Secondary | Number of Subjects With Vaccine Response to Havrix | Vaccine response to Havrix is defined as the appearance post-vaccination of anti-hepatitis A virus (anti-HAV) antibodies [concentration greater than or equal to 15 milli-international units per milliliter (mIU/mL)] in the serum of subjects seronegative before vaccination (concentration below the assay cut-off value of 15 mIU/mL) or having a 2-fold increase above the pre-vaccination concentration in subjects who were seropositive before vaccination. | At Day 42 after vaccination | |
Secondary | Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value | Cut-off value assessed include 0.05 micrograms per milliliter (µg/mL). | At Day 42 after vaccination | |
Secondary | Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value | Cut-off value assessed include 0.2 micrograms per milliliter (µg/mL). | At Day 42 after vaccination | |
Secondary | Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value | Cut-off value assessed include 0.5 micrograms per milliliter (µg/mL). | At Day 42 after vaccination | |
Secondary | Number of Subjects With Concentration of Antibodies to S. Pneumoniae Serotypes 4, 6B, 9V, 14, 18C, 19F and 23F Equal or Above the Cut-off Value | Cut-off value assessed include 1.0 micrograms per milliliter (µg/mL). | At Day 42 after vaccination | |
Secondary | Number of Subjects Reporting Solicited Local Symptoms | Solicited local symptoms assessed include pain, redness and swelling. | During the 4 day follow up period following vaccination | |
Secondary | Number of Subjects Reporting Fever = 38.0°C/100.4°F and > 39.5°C/103.1°F During the 15-day Follow up Period After Vaccination | Fever was measured rectally. | During the 15-day follow-up period following vaccination | |
Secondary | Number of Subjects Reporting Fever = 38.0°C/100.4°F and > 39.5°C/103.1°F During the 43-day Follow-up Period After Vaccination | Fever was measured rectally. | During the 43-day follow-up period following vaccination | |
Secondary | Number of Subjects Reporting Investigator-confirmed Measles/Rubella-like Rash | During the 43-day follow-up period after vaccination | ||
Secondary | Number of Subjects Reporting Investigator-confirmed Varicella-like Rash | During the 43-day follow-up period after vaccination | ||
Secondary | Number of Subjects Reporting Investigator-confirmed Parotid/Salivary Gland Swelling | During the 43-day follow-up period after vaccination | ||
Secondary | Number of Subjects Reporting Unsolicited Adverse Events and Medically-attended Adverse Events (Excluding Rash and Parotid/Salivary Gland Swelling) | Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Medically-attended adverse event covers any adverse event which received medical attention. Medical attention is defined as hospitalization, an emergency room visit or a visit to or from medical personnel. |
During the 43-day follow-up period after vaccination | |
Secondary | Number of Subjects Reporting New Onset Chronic Illnesses and Conditions Prompting Emergency Room Visits | New onset chronic illnesses include autoimmune disorders, asthma, type I diabetes and allergies. | For approximately 6 months (Day 0-180) | |
Secondary | Number of Subjects Reporting Serious Adverse Events | Serious adverse events assessed include medical occurrences that result in death, is life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. | For approximately 6 months (Day 0-180) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04183114 -
Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
|
Phase 2/Phase 3 | |
Completed |
NCT00092430 -
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
|
Phase 3 | |
Completed |
NCT02196285 -
Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
|
Phase 1 | |
Completed |
NCT00313950 -
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
|
Phase 4 | |
Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00402831 -
ProQuad® Intramuscular vs Subcutaneous
|
Phase 3 | |
Completed |
NCT00560755 -
Safety Study of ProQuad® rHA in Infants (V221-037)
|
Phase 3 | |
Completed |
NCT01878435 -
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
|
N/A | |
Completed |
NCT01777529 -
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
|
Phase 4 | |
Terminated |
NCT00258726 -
Immune Responses to Two Dose Varivax +/- MMR-II
|
Phase 1/Phase 2 | |
Completed |
NCT00109278 -
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
|
Phase 2 | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Completed |
NCT02880865 -
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
|
Phase 4 | |
Completed |
NCT01681992 -
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
|
Phase 3 | |
Completed |
NCT00751348 -
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
|
Phase 3 | |
Completed |
NCT01702428 -
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
|
Phase 3 | |
Completed |
NCT00969436 -
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
|
Phase 3 | |
Completed |
NCT00566527 -
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
|
Phase 3 | |
Completed |
NCT00127010 -
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
|
Phase 3 | |
Completed |
NCT00388440 -
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
|
Phase 4 |